Sector News

Bayer plots $1.6B investment at German pharma manufacturing sites, with digital transformation a key component

March 5, 2022
Life sciences

If you think Bayer’s recent $180 million sale of a drug manufacturing facility in Germany means the company is scaling back on production in its home country, think again.

Bayer plans to invest 1.4 billion euros ($1.55 billion) in its pharmaceuticals production sites in Bergkamen, Berlin, Leverkusen, Weimar and Wuppertal in the coming years, the German native said Thursday.

The money will be directed toward adding innovative technologies, new production facilities and digitization. The commitment is part of an agreement Bayer has signed with its works council to “strategically develop Bayer in Germany over the coming years and thus create the basis for sustainable employment growth from 2025 onwards,” according to a translated statement.

For the pharma division, Bayer also said it will continue to invest heavily in artificial intelligence, data science and multichannel marketing.

Last year, the company earmarked 250 million euros to build a new contraceptive product manufacturing plant in Turku, Finland. The plant boasts a heavy focus on new technologies including the adoption of automation and robotics to produce long-acting reversible contraceptives.

Bayer expects a large part of new pharma R&D hires planned by 2025 will happen in Germany. Its focus is on growth areas, especially cell and gene therapy and data science, the company said. The unit is currently modernizing and expanding its R&D sites in Berlin and Wuppertal.

The company has been nurturing its cell and gene therapy ambitions since its 2020 acquisition of Asklepios BioPharmaceutical for up to $4 billion. As part of a bigger plan to revamp its Berkeley, California, site in the U.S. that could eventually add about 1,000 employees, Bayer is said to be building a $200 million cell therapy facility at the location.

For 2021, Bayer spent 131 million euros on plants and equipment for cell and gene therapy research and production facilities in the U.S., Spain, Germany, the U.K. and Canada, according to its annual report.

Outside of pharma, Bayer will also invest 120 million euros over the next four years in its German consumer health sites in Bitterfeld, Darmstadt and Grenzach, the company said. The focus will be on digitization, smart factory technologies and employee training.

The crop science division will also see around 385 million euros of investment in digital methods and novel technologies plus an additional 300 million euros for property, plant and equipment.

Digital transformation is a key component for this investment round for the entire Bayer group across Germany. Toward that end, Bayer is establishing a Digital Innovation Center in Germany in 2022. Its initial focus will be “the development and broad application of advanced AI technologies and the further development of robot-supported process automation,” the statement said.

By Angus Liu

Source: fiercepharma.com

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach